(Gastric Cancer) Is Enhertu Effective?

• November 24, 2022
• Reading time: 1 minute

On November 15, 2022, Kensei Yamaguchi and colleagues from Cancer Institute Hospital published results in the Journal of Clinical Oncology from the DESTINY-Gastric01 Phase II clinical trial evaluating Enhertu (trastuzumab deruxtecan) in HER2-positive advanced gastric cancer or gastroesophageal junction (GEJ) cancer patients with two or more prior lines of therapy.

The DESTINY-Gastric01 Phase II trial was a multicenter open-label study that randomized HER2-positive advanced gastric cancer or GEJ cancer patients with ≥2 prior lines of therapy in a 2:1 ratio to the Enhertu arm (6.4 mg/kg every 3 weeks) or chemotherapy arm. Primary endpoint was objective response rate (ORR); secondary endpoints included disease control rate, progression-free survival (PFS), and overall survival (OS). Patients were classified into cohort 1 (N=21) and cohort 2 (N=24) based on HER2 classification.

Results:

ORR: cohort 1 26.3% / cohort 2 9.5%. Tumor shrinkage rate: cohort 1 68.4% (N=13) / cohort 2 60.0% (N=12).

Median OS: cohort 1 7.8 months / cohort 2 8.5 months. Median PFS: cohort 1 4.4 months / cohort 2 2.8 months.

Safety:

Grade ≥3 adverse events included anemia (cohort 1: 30.0% / cohort 2: 29.2%), neutropenia (cohort 1: 25.0% / cohort 2: 29.2%), and decreased appetite (cohort 1: 20.0% / cohort 2: 20.8%). Drug-induced interstitial lung disease was confirmed in one patient per cohort.

Based on the DESTINY-Gastric01 trial results, Kensei Yamaguchi and colleagues concluded that Enhertu demonstrated clinically meaningful antitumor activity in HER2-positive advanced gastric cancer or GEJ cancer patients with ≥2 prior lines of therapy.

Source: https://ascopubs.org/doi/full/10.1200/JCO.22.00575

• Clinical trial drugs

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4